Topics and Pearls
- Disease states such as acne, alopecia, atopic dermatitis, eczema hidradenitis suppurativa, prurigo nodularis, psoriasis, and rosacea
- Pearls for emerging therapeutics
- Conference data and pearls
Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
News
Article
Interview Intersection: Expert Interviews From October 2024
Author(s):
Key Takeaways
- Recent clinical trials emphasize the importance of evaluating treatment efficacy and safety across diverse populations, highlighting new data on roflumilast and zasocitinib.
- Biologic treatments are transforming the management of prurigo nodularis and atopic dermatitis, offering new therapeutic avenues for these conditions.
Dermatology Times is recapping our top expert interviews from the month of October.
Analyzing Efficacy and Safety in Diverse Clinical Trials: New Roflumilast Data
After releasing promising data from several clinical trials, Burnett discussed the importance of studying efficacy and safety across diverse populations.
Clinical Features and Cytokine Pathways in Prurigo Nodularis vs Atopic Dermatitis
Jason Hawkes, MD, MS, emphasized the importance of biologic treatments transforming the management of both prurigo nodularis and atopic dermatitis.
Valisure's David Light Shares Insights Into Newly-Published Benzene and BPO Data
Light delves into the science behind the new peer-reviewed data assessing benzene presence and formation in benzoyl peroxide products.
Phase 2b Trial Reinforces Zasocitinib’s Safety Profile
Melinda Gooderham, MSc, MD, FRCPC, emphasized the significance of the study’s results, showcasing stable laboratory parameters over a 12-week trial.
Q&A: Amy McMichael, MD, Discusses 48-Week VISIBLE Study Results on Psoriasis in Patients With Skin of Color
Over 70% of patients achieved clear or minimal skin by week 48, with a 90% retention rate in diverse patients with PsO.
Evan Rieder, MD: Immersion in the Eczema Patient Experience
AbbVie's Eczema Experience Pop-Up event recently provided attendees with immersive insights into the physical and psychosocial toll associated with eczema.
Benzene in Benzoyl Peroxide at Room Temperature: What Comes Next?
Christopher Bunick, MD, PhD, reviews the latest findings on benzene in benzoyl peroxide, highlighting the importance of proper storage and patient safety.
Philip Mease, MD, Discusses Head-to-Head BE BOLD Clinical Trial
Mease, the lead investigator on the trial, spoke about comparing varying mechanisms of action, primary and secondary endpoints, and how the results of BE BOLD could affect treatment choices.
Jessica Hui, MD: Non-Visible Considerations for Eczema Management
Hui addresses one of the NEA's Eczema Awareness Month weekly themes, "Eczema is more than the visuals."
Bimekizumab vs. Risankizumab: BE BOLD Study Insights with Jeff Stark
The study design emphasizes elevated endpoints, particularly joint health, ensuring that the most relevant outcomes are prioritized for patient care.
Chris Robb, MD, PhD, FAAD: Insights on the Latest Innovations in Skin Treatment Technology With BBL HEROic
Robb delved into how the system is transforming skin treatments with advanced precision, faster results, and improved patient outcomes.
Summer Forlenza, LMFT: Patient Resources for Breaking the Stress Cycle
Forlenza addresses one of the NEA's Eczema Awareness Month weekly themes, "Tools for living your most ecz-pressive life with eczema."
Peter Lio, MD: The Latest Perspectives on Pathophysiology and Treatment of Eczema
Lio addresses one of the NEA's Eczema Awareness Month weekly themes, "What is eczema?"
Addressing Unmet Needs Globally: LEO Pharma’s Commitment to Dermatology
Christophe Bourdon, CEO, discusses LEO Pharma's groundbreaking presentations at EADV, delgocitinib's US pending approval, and the company's commitment to addressing chronic hand eczema.
Vivian Shi, MD: Creative Approaches to Eczema Care
Shi addresses one of the NEA's Eczema Awareness Month weekly themes, "Creative ways to manage your eczema."
Navigating Complexities and Unmet Needs of Chronic Hand Eczema
Christopher Bunick, MD, PhD, addresses common barriers in recognizing and treating chronic hand eczema and its significant impact on quality of life.
Gearing Up for Fall Clinical 2024 With Raj Chovatiya, MD, PhD
The conference will feature presentations on a number of disease states, therapeutic options, and new clinical data.
The Latest in Dermatology With James Del Rosso, DO: Part 1
Del Rosso reviews numerous new and upcoming topical therapeutics and indications including ruxolitinib, tapinarof, and more.
The Latest in Dermatology With James Del Rosso, DO: Part 2
Del Rosso reviews available and upcoming monoclonal antibodies, including nemolizumab, lebrikizumab, bimekizumab, and more.
Game-Changing Insights on Itch, Psoriatic Disease, and Innovations With Mona Shahriari, MD, FAAD
Shahriari highlighted advanced dermatology treatments, clinical trial inclusivity, and key care strategies for complex skin conditions at Fall Clinical 2024.
Available Therapeutics and Upcoming Advancements in Atopic Dermatitis and Prurigo Nodularis
Shawn Kwatra, MD, reviews key highlights of his sessions at Fall Clinical 2024 on the latest updates in itch conditions.
Exploring Advancements in Palmoplantar Pustulosis, Psoriasis Comorbidities, and Phototherapy
Joel Gelfand, MD, discusses insights on complex psoriasis cases, comorbidity management, and the evolving role of phototherapy at Fall Clinical 2024.
Innovative Insights in Skin Cancer Prognosis, Gene Expression Profiling, and Early Career Tips
Aaron Farberg, MD, explores advancements in melanoma and cSCC prognostic tools, the role of gene expression profiling in inflammatory diseases, and initiatives aimed at supporting early-career dermatologists at Fall Clinical 2024.
Raj Chovatiya, MD, PhD: Current Disease States and Early Career Controversies
During an interview with Dermatology Times, Chovatiya outlined his Fall Clinical 2024 presentations on chronic and eczema and early career controversies.
James Song, MD, FAAD: Advanced Strategies for Alopecia Areata, Refractory Dermatoses, and Emerging Non-Steroidal Topicals
Song shared top clinical tips at Fall Clinical, covering alopecia areata, refractory dermatoses, and novel non-steroidal topicals.
Emmy Graber, MB, MBA, Shares Top Clinical Pearls on Lasers, Erythema Treatments, and Emerging Therapies
At Fall Clinical 2024, Graber spotlighted precise acne-targeting lasers, new combination creams, and a promising rosacea pill awaiting FDA approval.
Elevating Standards in Atopic Dermatitis Through JAK Inhibitors and Optimal Treatment Targets
At Fall Clinical 2024, Christopher Bunick, MD, PhD, discussed systemic therapy options and the importance of comprehensive treatment targets in managing atopic dermatitis, emphasizing AHEAD recommendations and LEVEL UP data.
Glynis Ablon, MD, Spotlights Top Devices and Innovations in Aesthetic Dermatology
At Fall Clinical 2024, Ablon shared her top device-based interventions, from wound care to radiofrequency rejuvenation, revealing clinical pearls for enhanced aesthetic outcomes.
Innovative Advances in Skin Cleansing with Zoe Diana Draelos, MD
A study of the new cleanser included diverse participants, ensuring it is suitable for various skin types and sensitivities.
Kristin Belleson: Navigating Eczema Awareness
Belleson addresses one of the NEA's Eczema Awareness Month weekly themes, “The eczema community is here to inspire you.”
Stephanie Manson Brown, MD, MBBS, MRCS: Allergan Aesthetics' Science of Aging and the Future of Aesthetic Medicine
Manson Brown discusses Allergan Aesthetics' Science of Aging program, highlighting its role in shifting from anti-aging to pro-longevity in aesthetic medicine.
Uncovering Systemic Corticosteroid Use and Updates on Long-Term Management Benefits of Upadacitinib in AD
At Fall Clinical 2024, Christopher Bunick, MD, PhD, presented findings on the prevalence of systemic corticosteroid use among patients with atopic dermatitis and highlighted how those treated with upadacitinib achieved and sustained optimal skin clearance and itch relief long-term.
Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.
Related Videos
Related Content
